| Followers | 141 |
| Posts | 5785 |
| Boards Moderated | 0 |
| Alias Born | 06/09/2020 |
Monday, June 12, 2023 8:45:44 AM
This is also why I'm hesitant to assign the same degree of credibility to the facts in Marnix Bosch's slide deck as I am to the facts published in an article in NEJM
How lucky then, that NWBO has two ongoing clinical trials ongoing at UCLA, one which has been running since 2010 in combo with poly-iclc and a SPORE trial with Keytruda, which Linda Liau has claimed have results during presentations of around 50-65% efficacy.
There is now an update to the preliminary results for the $NWBO UCLA DCVax-L + Poly-ICLC Combo trial.
— Tommy Bax 🇬🇧 🇹🇼 🇪🇺 (@TomBaxers) April 26, 2023
In Oct 2022 the slide deck was updated for Dr Liau's presentation. The KM Curve now shows a ~50% Overall Survival now approaching 10 YEARS. Pretty phenomenal stuff! pic.twitter.com/bNIx81pZGm
And then we have the Al Musella webinar with Liau, and a Q&A being censored by an unknown intermediary.
$NWBO
— 🇩🇰 The Danish Dude 🇬🇱 (@FlemmingBruce) May 23, 2023
The photo is from a slide used at the Al Musella webinar interviewing Linda Liau December 5th. 2022, which he was afterwards forced to take down.
The webinar also answered this:
POLY-ICLC - Hiltanol, approved - can get off label. https://t.co/DKT5mQQs1i pic.twitter.com/2Olf6ginCr
So its not that we are in need for any scientific qualifying of what Marnix Bosch presented to believe NWBO is about to become the biggest to hit cancer treatment for 3 decades.
We already have that.
But if what dr. Bosch presented will be scientifically corroborated, well then we'll have to do some further mulplying.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM


